PolyPid Regains European Rights as D-PLEX100 Application Wins EMA Validation
PolyPid Ltd. (PYPD) announced that the European Medicines Agency has validated its Marketing Authorization Application for its lead product candidate, D-PLEX100. The validation officially kicks off the formal review process in Europe, which could eventually result in a single approval applicable across all European Union member states. Alongside the regulatory milestone, the pharmaceutical company has reclaimed exclusive European commercialization rights for the treatment from ADVANZ Pharma, allowing it to negotiate new partnership terms.
This dual development is significant as it gives the company strategic control over its European launch. The regulatory submission is backed by positive Phase 3 clinical trial data, where the treatment met its primary and key secondary goals by demonstrating a 60% reduction in surgical site infection risk. Financially, the company remains stable with a cash runway extending into 2028, supported by a recent thirty million dollar payment from an agreement with Azurity.
Investors will now turn their attention to the United States, where the Food and Drug Administration is currently conducting a Priority Review of D-PLEX100. The FDA has set a target action date of November 28, 2026. A successful US decision and a potential new European partnership could serve as key next steps for the company's global expansion.
Key points
- The European Medicines Agency validated PolyPid's marketing application for D-PLEX100, starting the formal review process.
- PolyPid regained exclusive European commercialization rights for the asset from ADVANZ Pharma.
- The applications are supported by Phase 3 clinical trial data showing a 60% reduction in surgical site infection risk.
- The US FDA has granted Priority Review for D-PLEX100 with a decision date set for November 28, 2026.
- PolyPid's cash runway extends into 2028, supported by 30 million dollars received from a deal with Azurity.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the latest regulatory update for PolyPid?
The European Medicines Agency has validated PolyPid's Marketing Authorization Application for D-PLEX100, beginning the formal review process for potential approval across the European Union.
Why did PolyPid reclaim its European rights?
PolyPid regained exclusive European commercialization rights from ADVANZ Pharma, which enables the company to seek a new partnership on improved terms if the treatment is approved.
When is the US FDA decision date for D-PLEX100?
The US Food and Drug Administration is conducting a Priority Review for D-PLEX100, with a target action date of November 28, 2026.